Yanis Boumber

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1557/publications.pdf

Version: 2024-02-01

42 papers	2,763 citations	279798 23 h-index	289244 40 g-index
42 all docs	42 docs citations	42 times ranked	4795 citing authors

#	Article	IF	Citations
1	Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review). International Journal of Oncology, 2022, 60, .	3.3	25
2	The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors. Cellular and Molecular Life Sciences, 2022, 79, 285.	5.4	19
3	Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC). Oncogenesis, 2021, 10, 29.	4.9	18
4	Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC). Journal of Thoracic Disease, 2021, 13, 1370-1379.	1.4	7
5	Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. Cancers, 2021, 13, 3164.	3.7	35
6	Prognostic role and biologic features of Musashi-2 expression in colon polyps and during colorectal cancer progression. PLoS ONE, 2021, 16, e0252132.	2.5	5
7	Biomarkers for immune checkpoint inhibition in nonâ€“small cell lung cancer (NSCLC). Cancer, 2020, 126, 260-270.	4.1	202
8	CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma. British Journal of Cancer, 2020, 123, 1749-1756.	6.4	13
9	Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors. Frontiers in Oncology, 2020, 10, 576314.	2.8	17
10	Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. Advances in Therapy, 2019, 36, 2638-2678.	2.9	145
11	Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC). Cancers, 2019, 11, 1297.	3.7	21
12	An improved method of delivering a sclerosing agent for the treatment of malignant pleural effusion. BMC Cancer, 2019, 19, 614.	2.6	2
13	Case report: reinitiating pembrolizumab treatment after small bowel perforation. BMC Cancer, 2019, 19, 379.	2.6	14
14	The convergent roles of NF-Î°B and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma. Cell Death and Disease, 2018, 9, 374.	6.3	35
15	Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 4689-4693.	1.4	57
16	NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1171-1182.	4.9	192
17	Miliary Adenocarcinoma of the Lung Responds to Gefitinib and Afatinib. Journal of Thoracic Oncology, 2018, 13, e95-e97.	1.1	3
18	Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets. Clinical Cancer Research, 2017, 23, 2143-2153.	7.0	215

#	Article	IF	Citations
19	INST OXâ€05â€024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial. Cancer Medicine, 2017, 6, 2042-2051.	2.8	3
20	Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?. Cancer Biology and Therapy, 2017, 18, 940-943.	3.4	7
21	Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Frontiers in Oncology, 2016, 6, 112.	2.8	23
22	Recent Advances in Immunotherapy in Metastatic NSCLC. Frontiers in Oncology, 2016, 6, 239.	2.8	29
23	The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope. Future Oncology, 2016, 12, 2713-2727.	2.4	18
24	Anti-MÃ¼llerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer. Cell Reports, 2016, 16, 657-671.	6.4	47
25	Musashi-2 (MSI2) supports TGF-Î² signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6955-6960.	7.1	120
26	A Novel HSP90 Inhibitorâ€"Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 5120-5129.	7.0	28
27	Cancer Signature Investigation:ERBB2(HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 947-952.	4.9	13
28	A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2015, 21, 2704-2714.	7.0	56
29	Epigenetic Inactivation of Notch-Hes Pathway in Human B-Cell Acute Lymphoblastic Leukemia. PLoS ONE, 2013, 8, e61807.	2.5	44
30	A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia, 2012, 26, 2428-2431.	7.2	52
31	Final Report of a Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood, 2012, 120, 3567-3567.	1.4	1
32	Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opinion on Investigational Drugs, 2011, 20, 823-829.	4.1	98
33	DNA Methylation Profiles of Primary Colorectal Carcinoma and Matched Liver Metastasis. PLoS ONE, 2011, 6, e27889.	2.5	33
34	Final Report of a Randomized Study of Decitabine Versus Conventional Care (CC) for Maintenance Therapy in Patients with Intermediate and High Risk Acute Myeloid Leukemia (AML) in First or Subsequent Complete Remission (CR). Blood, 2011, 118, 1530-1530.	1.4	0
35	Epigenetics in cancer: what's the future?. Oncology, 2011, 25, 220-6, 228.	0.5	76
36	Chromatin Remodeling Is Required for Gene Reactivation after Decitabine-Mediated DNA Hypomethylation. Cancer Research, 2010, 70, 6968-6977.	0.9	81

#	Article	IF	Citations
37	Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nature Genetics, 2008, 40, 741-750.	21.4	554
38	Downregulation of Histone H3 Lysine 9 Methyltransferase G9a Induces Centrosome Disruption and Chromosome Instability in Cancer Cells. PLoS ONE, 2008, 3, e2037.	2.5	215
39	An Sp1/Sp3 Binding Polymorphism Confers Methylation Protection. PLoS Genetics, 2008, 4, e1000162.	3.5	64
40	RIL, a LIM Gene on 5q31, Is Silenced by Methylation in Cancer and Sensitizes Cancer Cells to Apoptosis. Cancer Research, 2007, 67, 1997-2005.	0.9	72
41	Drug Sensitivity Prediction by CpG Island Methylation Profile in the NCI-60 Cancer Cell Line Panel. Cancer Research, 2007, 67, 11335-11343.	0.9	104
42	In Vitro Effects of the Combination of Idarubicin (IDA) with Suberoylanilide Hydroxamic Acid (SAHA) or Valproic Acid (VPA) in Leukemia Cell Lines.. Blood, 2004, 104, 1173-1173.	1.4	0